KalVista Pharmaceuticals KALV Stock
KalVista Pharmaceuticals Price Chart
KalVista Pharmaceuticals KALV Financial and Trading Overview
| KalVista Pharmaceuticals stock price | 26.95 USD |
| Previous Close | 26.87 USD |
| Open | 26.92 USD |
| Bid | 19.39 USD x 200 |
| Ask | 26.99 USD x 100 |
| Day's Range | 26.92 - 26.98 USD |
| 52 Week Range | 9.83 - 26.98 USD |
| Volume | 2.6M USD |
| Avg. Volume | 3.29M USD |
| Market Cap | 1.43B USD |
| Beta (5Y Monthly) | -0.121 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.94 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.6 USD |
KALV Valuation Measures
| Enterprise Value | 1.43B USD |
| Trailing P/E | N/A |
| Forward P/E | 22.512472 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 12.528909 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 12.49 |
| Enterprise Value/EBITDA | -10.328 |
Trading Information
KalVista Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | -0.121 |
| 52-Week Change | 107.97% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 26.98 USD |
| 52 Week Low | 9.83 USD |
| 50-Day Moving Average | 22.5 USD |
| 200-Day Moving Average | 16.28 USD |
KALV Share Statistics
| Avg. Volume (3 month) | 3.29M USD |
| Avg. Daily Volume (10-Days) | 4.05M USD |
| Shares Outstanding | 53.24M |
| Float | 38.18M |
| Short Ratio | 1.98 |
| % Held by Insiders | 1.72% |
| % Held by Institutions | 131.35% |
| Shares Short | 12.05M |
| Short % of Float | 25.30% |
| Short % of Shares Outstanding | 22.63% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:14 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -118.74% |
| Operating Margin (ttm) | -57.36% |
| Gross Margin | 51.07% |
| EBITDA Margin | -120.93% |
Management Effectiveness
| Return on Assets (ttm) | N/A |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 114.48M USD |
| Revenue Per Share (ttm) | 2.11 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 58.47M USD |
| EBITDA | -138447008 USD |
| Net Income Avi to Common (ttm) | -135936992 USD |
| Diluted EPS (ttm) | -3.94 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 285.03M USD |
| Total Cash Per Share (mrq) | 5.35 USD |
| Total Debt (mrq) | 284.31M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 5.166 |
| Book Value Per Share (mrq) | -0.053 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -89319504 USD |
| Levered Free Cash Flow (ttm) | N/A |
Profile of KalVista Pharmaceuticals
| Country | United States |
| State | MA |
| City | Framingham |
| Address | 200 Crossing Boulevard |
| ZIP | 01702 |
| Phone | 857 999 0075 |
| Website | https://www.kalvista.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 275 |
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
Q&A For KalVista Pharmaceuticals Stock
What is a current KALV stock price?
KalVista Pharmaceuticals KALV stock price today per share is 26.95 USD.
How to purchase KalVista Pharmaceuticals stock?
You can buy KALV shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for KalVista Pharmaceuticals?
The stock symbol or ticker of KalVista Pharmaceuticals is KALV.
Which industry does the KalVista Pharmaceuticals company belong to?
The KalVista Pharmaceuticals industry is Biotechnology.
How many shares does KalVista Pharmaceuticals have in circulation?
The max supply of KalVista Pharmaceuticals shares is 53.24M.
What is KalVista Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
KalVista Pharmaceuticals PE Ratio is now.
What was KalVista Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
KalVista Pharmaceuticals EPS is -3.94 USD over the trailing 12 months.
Which sector does the KalVista Pharmaceuticals company belong to?
The KalVista Pharmaceuticals sector is Healthcare.
KalVista Pharmaceuticals KALV included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| US Tech Global Market Composite NQGM | 2296 USD — |
-1.38
|
— — | 2280.64 USD — | 2323.09 USD — | — - | — — |
| US Tech Biotechnology NBI | 5807.22 USD — |
+1.87
|
— — | 5685.34 USD — | 5809.82 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}